Portfolio concentration
As of February 28, 2026 · N-PORT
Holdings
44
Top-10 weight
47.79%
Effective holdings
?
The number of equal-weight positions that would produce this portfolio's concentration (1 ÷ Herfindahl index). A 500-stock fund dominated by a few mega-caps might have only ~100 effective holdings.
28
Crowding
?
The value-weighted average number of funds that also own this fund's positions. High = consensus/crowded picks; low = holdings few other funds own.
1178.0
Holdings
As of February 28, 2026 · N-PORT| # | Security | Ticker | Shares | Value | % of fund |
|---|---|---|---|---|---|
| 1 | LILLY ELI and CO | — | 5,263 | $5.54M | 10.01% |
| 2 | Roche Holding AG | — | 50,740 | $3.02M | 5.46% |
| 3 | JOHNSON&JOHNSON | — | 10,810 | $2.69M | 4.85% |
| 4 | ASTRAZENECA PLC | — | 12,706 | $2.66M | 4.81% |
| 5 | MERCK & CO | — | 18,918 | $2.34M | 4.23% |
| 6 | THERMO FISHER SCIENTIFIC INC | — | 4,137 | $2.16M | 3.90% |
| 7 | UNITEDHEALTH GRP | — | 7,253 | $2.13M | 3.85% |
| 8 | GILEAD SCIENCES INC | — | 13,435 | $2.00M | 3.62% |
| 9 | Novartis AG (Registered) | NVSEF | 11,781 | $2.00M | 3.61% |
| 10 | ABBOTT LABS | — | 16,017 | $1.86M | 3.37% |
| 11 | VERTEX PHARMACEUTICALS INC | — | 3,568 | $1.77M | 3.20% |
| 12 | ABBVIE INC | — | 7,045 | $1.64M | 2.96% |
| 13 | DANAHER CORP | — | 7,657 | $1.61M | 2.92% |
| 14 | BOSTON SCIENTIFIC CORP | — | 17,749 | $1.36M | 2.47% |
| 15 | MEDTRONIC PLC | — | 13,377 | $1.31M | 2.36% |
| 16 | BRIDGEBIO PHARMA INC | — | 18,567 | $1.23M | 2.23% |
| 17 | REVOLUTION MEDICINES INC | — | 11,995 | $1.22M | 2.21% |
| 18 | BRISTOL-MYERS SQUIBB CO | — | 19,189 | $1.20M | 2.16% |
| 19 | MCKESSON CORP | — | 1,210 | $1.19M | 2.16% |
| 20 | NOVO NORDISK-B | — | 31,589 | $1.19M | 2.15% |
| 21 | AMGEN INC | — | 2,984 | $1.16M | 2.09% |
| 22 | CHUGAI PHARMA CO | — | 16,971 | $1.14M | 2.05% |
| 23 | REGENERON PHARMACEUTICALS INC | — | 1,426 | $1.11M | 2.01% |
| 24 | EDWARDS LIFESCIENCES CORP | — | 11,887 | $1.03M | 1.86% |
| 25 | TEVA PHARMACEUTICAL IND ADR | — | 26,392 | $893.63K | 1.62% |
| 26 | CYTOKINETICS INC | — | 13,108 | $815.58K | 1.47% |
| 27 | INTUITIVE SURGICAL INC | — | 1,610 | $810.65K | 1.47% |
| 28 | MASIMO CORP | — | 4,286 | $751.55K | 1.36% |
| 29 | DEXCOM INC | — | 9,698 | $712.12K | 1.29% |
| 30 | MADRIGAL PHARMACEUTICALS INC | — | 1,551 | $670.03K | 1.21% |
| 31 | INSMED INC | — | 4,417 | $659.59K | 1.19% |
| 32 | ALNYLAM PHARMACEUTICALS INC | — | 1,972 | $656.52K | 1.19% |
| 33 | INSULET CORP | — | 2,336 | $576.08K | 1.04% |
| 34 | ARROWHEAD PHARMACEUTICALS INC | — | 8,970 | $567.53K | 1.03% |
| 35 | VIKING THERAPEUTICS INC | — | 13,867 | $469.26K | 0.85% |
| 36 | IONIS PHARMACEUTICALS INC | — | 5,673 | $460.36K | 0.83% |
| 37 | SCHOLAR ROCK HOLDING CORP | — | 9,773 | $432.65K | 0.78% |
| 38 | Ascendis Pharma A/S | — | 1,777 | $414.93K | 0.75% |
| 39 | CRINETICS PHARMACEUTICALS INC | — | 8,655 | $355.72K | 0.64% |
| 40 | FIRST AM-TR OB-X | TMPXX | 325,513 | $325.51K | 0.59% |
| 41 | NEUROCRINE BIOSCIENCES INC | — | 2,387 | $315.68K | 0.57% |
| 42 | ZEALAND PHARMA A | — | 5,363 | $308.54K | 0.56% |
| 43 | GUBRA A/S | — | 4,545 | $281.03K | 0.51% |
| 44 | INTELLIA THERAPEUTICS INC | — | 14,076 | $193.97K | 0.35% |
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.